VOR — Vor Biopharma Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1817229 ·
Last close
$19.13
Market Cap
$1.13B
52W High
$33.50
52W Low
$6.50
ADV30
1,132,280
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -47,853,000 | -62,810,000 | 481,053,000 | 107,855,000 | 681,250,000 |
| Mar 2026 | 0 | — | -35,160,000 | -219,585,000 | 506,746,000 | 169,873,000 | 657,170,000 |
| Dec 2025 | 0 | — | -35,960,000 | 1,722,858,000 | 464,126,000 | 396,486,000 | 628,438,000 |
| Sep 2025 | 0 | — | -28,107,000 | -812,684,000 | 176,237,000 | 160,462,000 | 2,401,724,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-149,893,000
Investing CF
$-311,809,000
Financing CF
$579,283,000
CapEx
$-758,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-383.15
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,372,560,000
Inventory
—
Receivables
—
ST Investments
$321,652,000
EBIT TTM
$-373,511,000
Pretax Income TTM
$-883,080,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -371,642,000 | -695,981,000 | 464,126,000 | 628,438,000 | -164,312,000 | -142,713,000 |
| Dec 2024 | 0 | -121,185,000 | -116,914,000 | 142,891,000 | 46,227,000 | 96,664,000 | -99,660,000 |
| Dec 2023 | 0 | -126,036,000 | -117,863,000 | 198,126,000 | 47,402,000 | 150,724,000 | -100,292,000 |
| Dec 2022 | 0 | -93,418,000 | -92,094,000 | 299,366,000 | 48,759,000 | 250,607,000 | -85,144,000 |
TTM Snapshot
Revenues TTM
$8,998,000
NetIncome TTM
$-883,080,000
OpCashFlow TTM
—
Assets (Latest)
$506,746,000
Forward EPS
$-3.81
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $19.13 · call volume: 56 · put volume: 301
Expected Move to 2027-05-21:
±$14.44
(75.48%) —
implied range
$4.69 –
$33.57
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMTX | Immatics N.V. | $1.12B | $7.37 | — |
| REPL | Replimune Group, Inc. | $1.23B | $13.04 | — |
| MGTX | MeiraGTx Holdings plc | $1.01B | $10.50 | — |
| CGEM | Cullinan Therapeutics, Inc. | $950.14M | $15.46 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.37B | $92.76 | — |
News headlines (Yahoo Finance, 1h cache)
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
2026-10-08 15:17 · Yahoo
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-05 22:00 · Yahoo
Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
2026-10-04 16:05 · Yahoo
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
2026-09-08 11:00 · Yahoo
Vor Bio To Participate in Upcoming September Conferences
2026-09-01 12:00 · Yahoo
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
2026-06-30 15:08 · Yahoo
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
2026-05-15 12:25 · Yahoo
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
2026-09-29 12:05 · Yahoo
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies |
2026-09-16 14:31 · Yahoo
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-11 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.